Momenta Pharmaceuticals Appoints Santiago Arroyo, M.D., Ph.D. as Chief Medical Officer
June 01 2017 - 8:00AM
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology
company specializing in the characterization and engineering of
complex drugs, today announced the appointment of Santiago Arroyo,
M.D., Ph.D. as Chief Medical Officer and Senior Vice President,
Development.
“Santiago’s deep understanding of successful
clinical development coupled with his experience as a principal
investigator on many trials, will be a huge asset to our expanding
pipeline of biosimilars and novel drugs for autoimmune diseases. I
am delighted to welcome him to our team,” said Craig A. Wheeler,
President and Chief Executive Officer of Momenta
Pharmaceuticals.
Dr. Arroyo joins Momenta from Boston
Pharmaceuticals, where he was Chief Medical Officer. Previously he
was Senior Vice President, Head of Clinical Research and Chief
Medical Officer of Biotherapeutics and Pharmatherapeutics at Pfizer
Inc. in the areas of Cardiovascular and Metabolism, Pain,
Neuroscience, Regenerative Medicine and Rare Diseases. He was
previously Therapeutic Area Head for Neurosciences, Discovery
Medicine and Clinical Pharmacology at Bristol-Myers Squibb and
Neurology Global Therapeutic Area Head for Eisai Global Clinical
Development. Dr. Arroyo was an Instructor in Neurology at the Johns
Hopkins Hospital and helped set up and run the epilepsy programs at
the Medical College of Wisconsin and Hospital Clinic of Barcelona,
Spain. Dr. Arroyo received his medical degree from the Autonomous
University of Madrid and his Ph.D. from the University of
Barcelona, Spain.
“This is an exciting time at Momenta as the
pipeline is both growing and advancing rapidly. We expect multiple
data readouts across the biosimilar and novel programs this year,”
said Dr. Arroyo. “Momenta’s understanding of innovative science and
efficient clinical development is extremely compelling and I look
forward to contributing to the development of products that will
change the lives of patients.”
About Momenta
Momenta Pharmaceuticals is a biotechnology
company specializing in the detailed structural analysis of complex
drugs and is headquartered in Cambridge, MA. Momenta is
applying its technology to the development of generic versions of
complex drugs, biosimilar and potentially interchangeable
biologics, and to the discovery and development of novel
therapeutics for autoimmune indications.
To receive additional information about Momenta,
please visit the website at www.momentapharma.com, which does
not form a part of this press release.
The company’s logo, trademarks, and service
marks are the property of Momenta Pharmaceuticals, Inc. All other
trade names, trademarks, or service marks are property of their
respective owners.
Forward-Looking Statements
Statements in this press release regarding
management's future expectations, beliefs, intentions, goals,
strategies, plans or prospects, are forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995, including but not limited to statements regarding the
Company’s pipeline; Dr. Arroyo’s expected impact on the Company’s
pipeline; and the timing of clinical trial results.
Forward-looking statements may be identified by words such as
“believe,” “continue,” “could,” “expect,” “guidance,” “may,”
“plan,” “potential,” “target,” “will” and other similar words or
expressions, or the negative of these words or similar words or
expressions. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors, including those
referred to under the section “Risk Factors” in the Company's
Quarterly Report on Form 10-Q for the year ended March 31,
2017, filed with the Securities and Exchange Commission,
as well as other documents that may be filed by the Company from
time to time with the Securities and Exchange
Commission. As a result of such risks, uncertainties and
factors, the Company's actual results may differ materially from
any future results, performance or achievements discussed in or
implied by the forward-looking statements contained
herein. The Company is providing the information in this press
release as of this date and assumes no obligations to update the
information included in this press release or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
INVESTOR CONTACT:
Sarah Carmody
Momenta Pharmaceuticals
1-617-395-5189
IR@momentapharma.com
MEDIA CONTACT:
Karen Sharma
MacDougall Biomedical Communications
1-781-235-3060
Momenta@macbiocom.com
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Apr 2023 to Apr 2024